Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 3/20 | 0.36 |
| ▸ | FPR2 | P25090 | 4/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5218296 | 0.86 | HTR2C (0.37) | SLC6A4SLC6A2SLC6A3HTR2CKCNH2 | |
| SCHEMBL5218302 | 0.83 | ALPG (0.38) | SLC6A4SLC6A2SLC6A3HTR2CKCNH2 | |
| SCHEMBL6929073 | 0.82 | HRH3 (0.49) | SLC6A4SLC6A2SLC6A3HTR2CKCNH2 | |
| SCHEMBL5333626 | 0.78 | SIGMAR1 (0.45) | SLC6A4SLC6A2SLC6A3HTR2CKCNH2 | |
| SCHEMBL6636548 | 0.78 | SIGMAR1 (0.45) | SLC6A4SLC6A2SLC6A3HTR2CKCNH2 | |
| SCHEMBL20205993 | 0.77 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3HTR2CKCNH2 | |
| SCHEMBL5336103 | 0.74 | SIGMAR1 (0.39) | SLC6A4SLC6A2SLC6A3HTR2CKCNH2 | |
| SCHEMBL6689767 | 0.74 | SIGMAR1 (0.39) | SLC6A4SLC6A2SLC6A3HTR2CKCNH2 | |
| SCHEMBL5331649 | 0.73 | SIGMAR1 (0.38) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 | |
| SCHEMBL5331646 | 0.73 | SIGMAR1 (0.38) | SLC6A4SLC6A2SLC6A3HTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663966-B1 | 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | NOVARTIS AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | LE GRAND DARREN M | 2007-02-22 | — | — | US | disclosed |
| EP-1663966-A1 | 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026113-A1 | 1, 3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | CCR1, CCR3, CCR9 | SLC6A4 3261/4885SLC6A2 3873/4885SLC6A3 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.